Ascendis Pharma AS (ASND): ASND 161 shares traded in pre-mkt. Take...

ASND 161 shares traded in pre-mkt. Take your

MiamiGent · 2023-05-03T13:38:14.6930000Z

ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate. Bearish

Play Episode

11min

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Buru Energy secures strategic deal for LNG development

Buru Energy Ltd CEO Thomas Nador talked with Proactive about the company’s newly announced strategic development agreement with Clean Energy Fuels Australia Pty Ltd (CEFA) to co-develop the Rafael Gas Project. Nador explained that CEFA brings strong midstream and downstream capabilities, backed by I Squared Capital, which manages around $40 billion in assets. "They bring the right credentials, to look after the downstream and midstream elements of the project," he said. Buru, meanwhile, will focus on the upstream side of the Rafael development. The deal is described as a “watershed moment” for the company, as it provides a clear pathway toward developing a long-term gas and condensate business in northwest Western Australia—an area currently dependent on imported energy. Under the agreement, CEFA will fund, build, and operate a small-scale LNG facility on-site, with Buru paying a processing fee over the life of the project. This significantly reduces Buru’s capital exposure to only the upstream infrastructure—namely, two wells, one of which is already in place. A final investment decision is expected in late 2025 or early 2026, with first cash flows anticipated in the second half of 2027. According to Nador, the projected annual free cash flow from the Rafael development is expected to surpass the company’s current market capitalization. For more insights like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates. #BuruEnergy #RafaelGasProject #LNGDevelopment #AustralianEnergy #CleanEnergy #GasExploration #CEFA #ThomasNador #ProactiveInvestors #ASXEnergy #NaturalGas #EnergyInfrastructure #I2Capital #UpstreamEnergy #MidstreamDevelopment

Proactive - Interviews for investors

Inspired PLC CEO Mark Dickinson breaks down FY24 highlights, net zero strategy

Inspired PLC (AIM:INSE) chief executive Mark Dickinson takes Proactive's Stephen Gunnion through the company's 2024 financial results, its ongoing mission to help clients reach net zero, and the outlook for 2025. Dickinson provided an overview of the group’s four complementary divisions: software, assurance, ESG, and optimisation. These work together to help Inspired’s B2B clients manage energy costs, comply with ESG reporting obligations, and implement real carbon reduction strategies. “The backdrop continues to be increasingly favourable for Inspired as we help those clients navigate their way through those challenges,” Dickinson said, citing continuing demand despite lower energy prices. FY24 was a year focused on strengthening the balance sheet. Dickinson said the company eliminated all contingent consideration liabilities, raised capital, and reduced net leverage from 2.59x to 1.47x adjusted EBITDA—giving the business a firmer platform for growth. The company’s non-financial KPIs also moved in a positive direction, with cross-selling increasing and more than 50% of optimisation clients returning for additional services. Inspired is now serving 420 clients with optimisation support. Looking ahead, Dickinson said trading in 2025 started in line with expectations, and the business is progressing well on previously delayed projects. He remains optimistic about the pipeline and demand drivers, particularly in energy conservation, ESG compliance, and net zero support. For more CEO interviews and company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and enable notifications so you never miss an update. #InspiredPLC #NetZero #EnergyEfficiency #ESG #CarbonReduction #SustainabilityGoals #CleanEnergy #GreenBusiness #UKStocks #ProactiveInvestors

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Followers	276
Posts	54415
Boards Moderated	3
Alias Born	08/16/2008

Volume:	521,647
Day Range:	134.34 - 146.44
Bid:	134.76
Ask:	139.50
Last Trade Time:	4:30:50 PM EDT
Total Trades:	11,291

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ASND Detailed Quote

Recent ASND News

More ASND News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ASND News

Go Ad-Free